SIRT6-IN-3
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research[1].
Product Specifications
CAS Number
3023471-40-8
UNSPSC
12352005
Target
Akt; ERK; HDAC; mTOR; Ribosomal S6 Kinase (RSK) ; Sirtuin
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/sirt6-in-3.html
Purity
98.19
Solubility
DMSO : ≥ 120 mg/mL
Smiles
BrC1=C(Br)NC(C2=NC=CC3=C2N=CN3CCCCCCS/C(N(C)C)=[N+](C)\C)=C1.Cl.[Br-]
Molecular Formula
C21H30Br3ClN6S
Molecular Weight
673.73
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC3; HDAC6; HDAC8; SIRT1; SIRT2; SIRT6
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ACTH (Adrenocorticotrophic Hormone) (AH26), CF640R conjugate, 0.1mg/mL
Cytokeratin 8/18 (C-51), CF405S conjugate, 0.1mg/mL
CD45 / LCA (2B11 + PD7/26), CF594 conjugate, 0.1mg/mL
